Latest news with #AmgenInc
Yahoo
24-05-2025
- Business
- Yahoo
With 81% institutional ownership, Amgen Inc. (NASDAQ:AMGN) is a favorite amongst the big guns
Institutions' substantial holdings in Amgen implies that they have significant influence over the company's share price A total of 20 investors have a majority stake in the company with 50% ownership Recent sales by insiders We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. A look at the shareholders of Amgen Inc. (NASDAQ:AMGN) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 81% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's take a closer look to see what the different types of shareholders can tell us about Amgen. View our latest analysis for Amgen Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Amgen already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Amgen, (below). Of course, keep in mind that there are other factors to consider, too. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. We note that hedge funds don't have a meaningful investment in Amgen. Our data shows that The Vanguard Group, Inc. is the largest shareholder with 9.8% of shares outstanding. With 8.4% and 6.9% of the shares outstanding respectively, BlackRock, Inc. and Capital Research and Management Company are the second and third largest shareholders. After doing some more digging, we found that the top 20 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Our information suggests that Amgen Inc. insiders own under 1% of the company. Being so large, we would not expect insiders to own a large proportion of the stock. Collectively, they own US$221m of stock. Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling. With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Amgen. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Amgen you should be aware of. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Enbrel (Etanercept) Market Research Report 2025: Epidemiology, Pipeline Analysis, Insights & Forecasts 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Enbrel (Etanercept) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to Enbrel (Etanercept) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Enbrel (etanercept) is a biologic medication that treats various autoimmune conditions by inhibiting the activity of tumor necrosis factor (TNF), a protein involved in inflammation. It is a synthetic version of a naturally occurring protein in the body, designed to bind to TNF and block its interaction with its receptors, reducing inflammation. Enbrel is usually administered through subcutaneous injection, either by a healthcare professional or by patients themselves at home. Major players operating in the enbrel (etanercept) market are Amgen Inc; Pfizer Inc. North America was the largest region in the enbrel (etanercept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in enbrel (etanercept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enbrel (etanercept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, primary types of enbrel (etanercept) include brand drugs and biosimilars. It is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis by blocking TNF. Enbrel is available in both liquid solution and powder for injection growth observed during the historic period can be attributed to the approval of multiple indications, strong adoption by physicians, the introduction of patient-friendly injection devices, a growing healthcare focus on cost-effective treatments for chronic diseases, extensive clinical trials, and positive growth during the forecast period can be driven by the aging global population, the increasing prevalence of autoimmune diseases, rising preference for biologics, the introduction of biosimilars, and increased government funding and insurance coverage. Key trends during this period include its use in pediatric populations, a rise in home-based treatments, integration of digital health, combination therapy approaches, and advancements in genomics and biomarker surging prevalence of autoimmune conditions is expected to significantly propel the growth of the enbrel (etanercept) market. Autoimmune conditions, where the immune system mistakenly attacks the body's healthy tissues, are increasing due to factors such as genetic susceptibility, environmental triggers, and improved diagnosis and awareness. Enbrel, which inhibits tumor necrosis factor-alpha (TNF-a), is highly effective in treating autoimmune disorders such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By blocking TNF-a, Enbrel helps reduce inflammation, alleviate symptoms, and slow disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 Australians were living with rheumatoid arthritis in 2022. The increasing prevalence of such conditions will continue to drive demand for enbrel.A key trend in the enbrel (etanercept) market is the development of innovative TNF inhibitors to manage autoimmune diseases. TNF inhibitors block the TNF protein, which is responsible for inflammation and immune responses, thereby helping to reduce symptoms like joint swelling and pain. In October 2023, Amgen Inc. received U.S. Food and Drug Administration (FDA) approval for Enbrel to manage juvenile psoriatic arthritis (JPsA) in children aged two and older. This approval marks a significant advancement in the use of Enbrel for younger Topics Covered: 1. Executive Summary2. Enbrel (Etanercept) Market Characteristics3. Enbrel (Etanercept) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Enbrel (Etanercept) Market Trends and Strategies5. Enbrel (Etanercept) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Enbrel (Etanercept) Growth Analysis and Strategic Analysis Framework6.1. Global Enbrel (Etanercept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Enbrel (Etanercept) Market Growth Rate Analysis6.4. Global Enbrel (Etanercept) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Enbrel (Etanercept) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Enbrel (Etanercept) Total Addressable Market (TAM)7. Global Enbrel (Etanercept) Market Pricing Analysis & Forecasts8. Enbrel (Etanercept) Market Segmentation8.1. Global Enbrel (Etanercept) Market, Segmentation by Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Brands Drugs Biosimilar Drugs 8.2. Global Enbrel (Etanercept) Market, Segmentation by Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Liquid Solution Powder For Injections 8.3. Global Enbrel (Etanercept) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis Juvenile Idiopathic Arthritis 9. Global Enbrel (Etanercept) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Enbrel (Etanercept) Market Regional and Country Analysis10.1. Global Enbrel (Etanercept) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Enbrel (Etanercept) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
11-05-2025
- Business
- Yahoo
Interested In Amgen's (NASDAQ:AMGN) Upcoming US$2.38 Dividend? You Have Four Days Left
Readers hoping to buy Amgen Inc. (NASDAQ:AMGN) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is usually set to be one business day before the record date, which is the cut-off date on which you must be present on the company's books as a shareholder in order to receive the dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least one business day to settle. Accordingly, Amgen investors that purchase the stock on or after the 16th of May will not receive the dividend, which will be paid on the 6th of June. The company's upcoming dividend is US$2.38 a share, following on from the last 12 months, when the company distributed a total of US$9.52 per share to shareholders. Calculating the last year's worth of payments shows that Amgen has a trailing yield of 3.6% on the current share price of US$265.86. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. We need to see whether the dividend is covered by earnings and if it's growing. Our free stock report includes 2 warning signs investors should be aware of before investing in Amgen. Read for free now. Dividends are usually paid out of company profits, so if a company pays out more than it earned then its dividend is usually at greater risk of being cut. Its dividend payout ratio is 83% of profit, which means the company is paying out a majority of its earnings. The relatively limited profit reinvestment could slow the rate of future earnings growth. We'd be concerned if earnings began to decline. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Fortunately, it paid out only 45% of its free cash flow in the past year. It's positive to see that Amgen's dividend is covered by both profits and cash flow, since this is generally a sign that the dividend is sustainable, and a lower payout ratio usually suggests a greater margin of safety before the dividend gets cut. View our latest analysis for Amgen Click here to see the company's payout ratio, plus analyst estimates of its future dividends. Companies with falling earnings are riskier for dividend shareholders. Investors love dividends, so if earnings fall and the dividend is reduced, expect a stock to be sold off heavily at the same time. So we're not too excited that Amgen's earnings are down 3.2% a year over the past five years. The main way most investors will assess a company's dividend prospects is by checking the historical rate of dividend growth. Since the start of our data, 10 years ago, Amgen has lifted its dividend by approximately 15% a year on average. The only way to pay higher dividends when earnings are shrinking is either to pay out a larger percentage of profits, spend cash from the balance sheet, or borrow the money. Amgen is already paying out 83% of its profits, and with shrinking earnings we think it's unlikely that this dividend will grow quickly in the future. Has Amgen got what it takes to maintain its dividend payments? We're not enthused by the declining earnings per share, although at least the company's payout ratio is within a reasonable range, meaning it may not be at imminent risk of a dividend cut. All things considered, we are not particularly enthused about Amgen from a dividend perspective. If you want to look further into Amgen, it's worth knowing the risks this business faces. Our analysis shows 2 warning signs for Amgen and you should be aware of them before buying any shares. Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Business
- Yahoo
Is Amgen Inc. (AMGN) the Best Dow Stock?
We recently published a list of . In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other Dow stocks. The Dow Jones Industrial Average is a benchmark index of the top 30 companies in the US. It represents the strength of the US economy and carries great historical significance as well. It also acts as a reference point for analysts and investors. However, not all stocks within this elite group of companies perform equally. While some thrive on innovation and economic boom, others struggle due to various setbacks and economic trends. We decided to break down the index and find out the best and worst stocks, looking at what was making them perform unexpectedly this year. In order to come up with our ranking of the best and worst Dow stocks, we first assigned a rank to each stock based on the number of hedge funds holding the stock. We then looked at the short interest in each stock and assigned the top rank to the company with the least short interest. We then combined the two ranks to see which stock was the best on average. The list is in ascending order, with the best stock taking the number one spot. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A pharmacist filling a prescription for a complex drug developed by the Interest as of Apr 30, 2025: 2.71% Amgen Inc. (NASDAQ:AMGN) operates as a manufacturer, developer, discoverer, and deliverer of human therapeutics. Its key product candidates are Enbrel, XGEVA, Otezla, KYPROLIS, Prolia, Repatha, Nplate, Aranesp, EVENITY, Vectibix, BLINCYTO, and others. It serves dialysis centers, pharmacies, hospitals, and physicians. The firm recently announced plans to invest an additional $900 million to expand its Ohio biotech manufacturing facility. According to Bloomberg's report, this expansion will create hundreds of new jobs. This move will help the company to improve its global biomanufacturing network. Chairman and CEO at Amgen, Robert A. Bradway commented: 'Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today's investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines. Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.' At the start of this month, the firm received an expanded FDA label approval for Uplizna. The FDA has approved it as the first treatment for Immunoglobulin G4-related disease (IgG4-RD) for adults. This approval is based on the late-stage clinical trial results indicating that Uplizna reduced the risk of disease reactivation by 87%. Overall, AMGN ranks 28th on our list of best and worst Dow stocks. While we acknowledge the potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AMGN but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-05-2025
- Business
- Yahoo
Is Amgen Inc. (AMGN) the Best Dow Stock for the Next 12 Months?
We recently published a list of . In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the Dow, is a price-weighted index that has long been seen as a barometer of the health of the U.S. economy. After touching all-time highs in late November 2024, the index has corrected nearly 7% in 2025 (as of April 23) and is down 12% from its highs. Rightly so, the correction reflects several unfavourable developments, including economic uncertainties and geopolitical tensions weighing on economic growth. The market is expected to remain volatile as the trade and other aspects of the US administration's policy agenda play out. Amid this volatility, based on the potential for share price appreciation in the next 12 months, we have created a selection of the best and worst Dow stocks from the 30 Dow constituent stocks. If we analyse its trackable history from 1899, the Dow has fallen 7% or more on a single day twenty times. Of those, only seven occurred after the year 2000, and the 5.5% decline on April 5, 2025, doesn't count as one of those seven, or not even in the historical top twenty. So, technically, this correction was not as severe as earlier. From corrections post 2000, the sharp declines when Covid-19 struck were the most noticeable – Dow fell 7.8%, 10%, and 12% on 9, 12, and 16th March, respectively, and saw further significant declines in that year. That said, the current period remains one of the most confusing times for market participants, even for the larger players in the equity market, who remain uncertain about their estimates for the broader markets, such as the Dow. In a recent interview, Lauren Goodwin, Chief Market Strategist at New York Life Investments, emphasized that the fundamental picture remains cloudy and investors are still looking for clarity in macroeconomic fundamentals. Despite some positive economic data recently, policy uncertainty is limiting visibility. As more data is released, she believes markets are entering a sustained period of elevated volatility across equities and fixed income. In these testing times, investors should examine fundamentals more critically, preferring Dow stocks with earnings resilience, clear competitive advantages, and exposure to long-term, secular growth themes. On April 28, Stephanie Link, Hightower Advisors' chief investment strategist, shared her positive outlook on the stock market in an interview on CNBC. With major tech companies, consumer, and financial companies set to announce results, she believes that if corporate earnings remain strong, the recent market rebound could continue. Since early April, the market has recovered significantly, and she attributed the rally to better-than-expected profit margins and steady corporate performance. Although the prominent tech names aren't cheap in terms of valuation, she views the recent declines as long-term buying opportunities. While markets may remain volatile in the coming months, the best opportunities in the Dow over the next 12 months should come from stocks with strong pricing power and earnings momentum. Investors should stick to stocks with strong brands, recurring revenue models, and competitive moats, which enable them to navigate macro uncertainty. Since the Dow comprises large-cap companies across various industries, these stocks might perform better during sell-offs. To identify the best and worst Dow stocks, we began with the 30 constituent stocks of the DJIA Index. We then ranked these stocks in ascending order based on the consensus 1-year median potential upside. Additionally, we also include data on hedge funds holding stakes in these stocks, utilizing Insider Monkey's Q4 2024 hedge fund database to provide deeper insights into institutional investor trends. It is important to note here that the terms 'best' and 'worst' refer strictly to the relative upside potential and do not imply any fundamental strengths or weaknesses of the underlying are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (see more details here). A pharmacist filling a prescription for a complex drug developed by the Inc. (NASDAQ:AMGN) is a pioneer in the biotechnology industry. It develops, manufactures, and sells innovative medicines for some of the most serious diseases, including cancer, heart disease, and osteoporosis. Close to ten of Amgen Inc.'s (NASDAQ:AMGN) products delivered at least double-digit sales growth, which helped the company's 2024 revenue climb 19% YoY to $33.4 billion. It expects to report revenue in the $34.3-35.7 billion range in 2025. In 2024, the company spent around $6 billion on R&D, up 25% year over year and equating to around 18.5% of total revenue. With that kind of R&D focus, the company has a strong pipeline of potentially best-in-class medicines across many therapeutic areas. The U.S. Food and Drug Administration (FDA) approved UPLIZNA as the first and only treatment for Immunoglobulin G4-related disease (IgG4-RD) in early March. This immune-mediated inflammatory condition can affect multiple organs. In their latest updates in the last two weeks, analysts from Bernstein, Piper Sandler, and Jefferies have reiterated their Buy rating on the stock. Overall, AMGN ranks 20th on our list of best and worst dow stocks for the next 12 months. While we acknowledge the potential of Dow stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AMGN but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
